Revolution Medicines (RVMD)
(Real Time Quote from BATS)
$46.02 USD
+1.62 (3.65%)
Updated Sep 25, 2024 10:42 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Revolution Medicines, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -436.37 | -248.71 | -187.09 | -108.16 | -47.66 |
Depreciation/Amortization & Depletion | -12.90 | 6.58 | 10.34 | 7.51 | 2.89 |
Net Change from Assets/Liabilities | 40.66 | -13.07 | 8.72 | -7.93 | -4.45 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 58.03 | 30.80 | 20.84 | 8.51 | -0.39 |
Net Cash From Operating Activities | -350.57 | -224.40 | -147.18 | -100.06 | -49.62 |
Property & Equipment | -7.73 | -10.82 | -6.53 | -2.93 | 3.61 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -334.87 | -13.30 | -135.59 | -231.30 | -105.58 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -342.60 | -24.12 | -142.12 | -234.23 | -101.97 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 1,233.23 | 301.39 | 294.60 | 422.78 | 100.26 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -4.03 | 0.04 | -0.42 | 0.00 | -1.60 |
Net Cash from Financing Activities | 1,229.20 | 301.43 | 294.18 | 422.78 | 98.66 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 536.03 | 52.92 | 4.88 | 88.48 | -52.93 |
Cash at Beginning of Period | 163.15 | 110.23 | 105.35 | 16.87 | 69.80 |
Cash at End of Period | 699.18 | 163.15 | 110.23 | 105.35 | 16.87 |
Diluted Net EPS | -3.86 | -3.08 | -2.57 | -2.01 | -22.33 |
Fiscal Year End for Revolution Medicines, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -249.24 | -116.00 | -436.37 | -274.83 | -166.40 |
Depreciation/Amortization & Depletion | -20.59 | -12.48 | -12.90 | -7.12 | -4.12 |
Net Change from Assets/Liabilities | -51.95 | -47.21 | 40.66 | 19.46 | 18.33 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 33.05 | 15.14 | 58.03 | 32.48 | 22.68 |
Net Cash From Operating Activities | -288.73 | -160.56 | -350.57 | -230.01 | -129.51 |
Property & Equipment | -5.57 | -3.17 | -7.73 | -5.41 | -2.88 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -134.46 | -244.80 | -334.87 | 43.22 | -36.67 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -140.02 | -247.97 | -342.60 | 37.80 | -39.55 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 8.31 | 0.81 | 1,233.23 | 389.85 | 388.84 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -4.03 | 0.00 | 0.00 |
Net Cash from Financing Activities | 8.31 | 0.81 | 1,229.20 | 389.85 | 388.84 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -420.44 | -407.72 | 536.03 | 197.64 | 219.78 |
Cash at Beginning of Period | 699.18 | 699.18 | 163.15 | 163.15 | 163.15 |
Cash at End of Period | 278.74 | 291.46 | 699.18 | 360.79 | 382.92 |
Diluted Net EPS | -0.81 | -0.70 | -1.23 | -0.99 | -0.92 |